Zoetis
About: Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Employees: 13,800
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
76% more first-time investments, than exits
New positions opened: 247 | Existing positions closed: 140
4% more funds holding
Funds holding: 1,755 [Q3] → 1,830 (+75) [Q4]
1.22% more ownership
Funds ownership: 91.15% [Q3] → 92.37% (+1.22%) [Q4]
9% less repeat investments, than reductions
Existing positions increased: 654 | Existing positions reduced: 715
14% less call options, than puts
Call options by funds: $221M | Put options by funds: $258M
16% less capital invested
Capital invested by funds: $80.4B [Q3] → $67.9B (-$12.5B) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 26 [Q3] → 13 (-13) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$165
11%
upside
Avg. target
$213
43%
upside
High target
$244
64%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Stifel Jonathan Block 0% 1-year accuracy 0 / 20 met price target | 11%upside $165 | Buy Maintained | 14 Apr 2025 |
Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target | 38%upside $205 | Overweight Maintained | 27 Feb 2025 |
Barclays Balaji Prasad 18% 1-year accuracy 8 / 44 met price target | 64%upside $244 | Overweight Maintained | 14 Feb 2025 |
Morgan Stanley Erin Wright 52% 1-year accuracy 13 / 25 met price target | 60%upside $238 | Overweight Maintained | 14 Feb 2025 |
Financial journalist opinion
Based on 6 articles about ZTS published over the past 30 days
Positive
The Motley Fool
2 weeks ago
This Magnificent Dividend Stock Has Increased Its Payouts by 500% in 10 Years
There are many dividend stocks on equity markets, but not all are attractive to income investors. Those that go beyond paying a quarterly payout but also consistently raise their dividends -- all while having robust businesses that can support their dividend programs for a long time -- are the ones income-seekers want.
Positive
Seeking Alpha
2 weeks ago
My Top 15 High-Growth Dividend Stocks For April 2025
My Top 15 High-Growth Dividend stocks outperformed SPY and VIG in March, posting a loss of 3.26% compared to SPY's 5.86% and VIG's 4.50%. The April 2025 list offers an average dividend yield of 1.25% and is potentially 31% undervalued, poised for strong long-term returns. Dollar cost averaging into the top 15 stocks each month shows a 68.54% success rate, with 61 out of 89 stocks leading to positive gains.
Negative
The Motley Fool
3 weeks ago
Zoetis' Stock Is About as Cheap as It's Ever Been. 1 Thing to Know Before You Buy.
Shares in animal pharmaceutical company Zoetis (ZTS 0.14%) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but the company's revenue guidance fell short of expectations.
Neutral
Business Wire
3 weeks ago
Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, May 6, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2025 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations.
Positive
Seeking Alpha
3 weeks ago
Zoetis: Lots Of Growth Opportunities For This High-Quality Compounder
Zoetis is currently cheap from a historical perspective, presenting a potential buying opportunity. The company operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization, ensuring long-term growth. ZTS has a strong track record of market outperformance, impressive margins, and a high ROIC, making it a high-quality company.
Neutral
Zacks Investment Research
3 weeks ago
Zoetis (ZTS) Stock Declines While Market Improves: Some Information for Investors
Zoetis (ZTS) closed the most recent trading day at $163.03, moving -0.08% from the previous trading session.
Neutral
Zacks Investment Research
1 month ago
Why Zoetis (ZTS) Dipped More Than Broader Market Today
The latest trading day saw Zoetis (ZTS) settling at $160.06, representing a -1% change from its previous close.
Positive
Seeking Alpha
1 month ago
Zoetis: Focusing On The High Margin Segments
The recent divestiture of the MFA segment improves margins and returns on capital. Zoetis is focusing on more profitable segments like genetics and companion animals. The recently updated Librela label includes adverse effects and urges practitioners to discuss potential adverse reactions with clients.
Neutral
Seeking Alpha
1 month ago
Zoetis Inc. (ZTS) CFO Wetteny Joseph Hosts Barclays 27th Annual Global Healthcare (Transcript)
Zoetis Inc. (NYSE:ZTS ) Barclays 27th Annual Global Healthcare March 11, 2025 10:30 AM ET Company Participants Wetteny Joseph - Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. Thanks for joining us at the Barclays Healthcare Conference.
Neutral
Zacks Investment Research
1 month ago
Zoetis (ZTS) Laps the Stock Market: Here's Why
Zoetis (ZTS) reachead $170.37 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.
Charts implemented using Lightweight Charts™